Colleen Silk on Novo Nordisk Performance at ASH25
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”I’m so proud to have attended the 2025 ASH Annual Meeting in Orlando over the weekend alongside so many talented colleagues from our Hemoglobinopathies and Rare Blood Disorders teams.
It was so inspiring to see the dedication, expertise, and collaboration that went into making this meeting such a success for Novo Nordisk.
In addition to the great work that went into our exhibit booth and many poster and oral presentations, ASH was an invaluable opportunity to engage directly with the hematology community.
We had meaningful conversations with KOLs where we shared the science and our vision for expanding treatment options for people living with rare blood disorders and sickle cell disease.
These dialogues will help shape our path forward and accelerate the impact of our future portfolio.
A huge thank you to everyone who worked so hard to bring this to life.
From our US Field and Home Office cross-functional teams and our partners in Global, everyone contributed to making the congress truly outstanding.
I’m excited for what lies ahead for the Rare Disease team at Novo Nordisk as we continue to educate with the goal of bringing innovative therapies to patients who need them most.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC